{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T14:31:02Z","timestamp":1790173862806,"version":"4.1.0"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T00:00:00Z","timestamp":1526947200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Pharmacyclics LLC"},{"name":"Janssen trial registration","award":["NCT02427620"],"award-info":[{"award-number":["NCT02427620"]}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Br J Haematol"],"published-print":{"date-parts":[[2018,8]]},"abstract":"<jats:title>Summary<\/jats:title>\n                  <jats:p>\n                    Ibrutinib has shown significant activity in patients with relapsed or refractory mantle cell lymphoma (\n                    <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    ). We report the long\u2010term outcome and safety profile of a single\u2010centre, single arm, open\u2010label, phase 2 study of\n                    <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    treated with\n                    <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                    . Overall, the median follow\u2010up time was 47\u00a0months (range 1\u201352\u00a0months), median duration on treatment was 16\u00a0months (range 1\u201353\u00a0months) and median number of treatment cycles was 17 (range 1\u201356). Twenty\u2010nine patients (58%) achieved complete remission and of these, 12 patients continue on study. Thirty\u2010eight patients discontinued treatment, 14 due to disease progression (2 transformed). Patients with blastoid morphology, high risk\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    International Prognostic Index score and high Ki67% had inferior survival. The commonest grade 1\u20132 toxicities were fatigue, diarrhoea, nausea, arthralgias and myalgias. None had long term toxicities. Median progression\u2010free survival was 43\u00a0months. Eighteen patients (36%) died (14 deaths were\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    \u2010related). The median overall survival has not been reached. Treatment with\n                    <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                    can provide durable remissions in a subset of patients with\n                    <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    , especially those with low Ki67%. The possible benefit of adding other therapies in combination with\n                    <jats:styled-content style=\"fixed-case\">IR<\/jats:styled-content>\n                    in\n                    <jats:styled-content style=\"fixed-case\">RR<\/jats:styled-content>\n                    \u2010\n                    <jats:styled-content style=\"fixed-case\">MCL<\/jats:styled-content>\n                    is under exploration.\n                  <\/jats:p>","DOI":"10.1111\/bjh.15411","type":"journal-article","created":{"date-parts":[[2018,5,22]],"date-time":"2018-05-22T04:00:41Z","timestamp":1526961641000},"page":"404-411","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":64,"title":["Four\u2010year follow\u2010up of a single arm, phase\n                    <scp>II<\/scp>\n                    clinical trial of ibrutinib with rituximab (\n                    <scp>IR<\/scp>\n                    ) in patients with relapsed\/refractory mantle cell lymphoma (\n                    <scp>MCL<\/scp>\n                    )"],"prefix":"10.1111","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2735-168X","authenticated-orcid":false,"given":"Preetesh","family":"Jain","sequence":"first","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4830-9173","authenticated-orcid":false,"given":"Jorge","family":"Romaguera","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samer A.","family":"Srour","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hun J.","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frederick","family":"Hagemeister","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason","family":"Westin","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Fayad","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"Samaniego","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Badillo","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lorreta","family":"Nastoupil","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7829-5249","authenticated-orcid":false,"given":"Rashmi","family":"Kanagal\u2010Shamanna","sequence":"additional","affiliation":[{"name":"Department of Hematopathology The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nathan","family":"Fowler","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael L.","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Lymphoma and myeloma The University of Texas MD Anderson Cancer Center Houston TX USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2018,5,22]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(11)70062-6"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12185-016-2164-2"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.13796"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-16-1431"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2016.70.4320"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(15)00667-4"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdn656"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.49.2835"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2008.20.7977"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2013.52.2466"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2013-11-537555"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-10-673145"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-04-015586"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14870"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375\u2010018\u20100023\u20102"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00559-8"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70200-0"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1306220"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2015-03-635326"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(15)00438-6"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33108-2"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1182\/asheducation-2015.1.355"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdt366"}],"container-title":["British Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjh.15411","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjh.15411","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,14]],"date-time":"2023-09-14T14:46:59Z","timestamp":1694702819000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/bjh.15411"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,5,22]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2018,8]]}},"alternative-id":["10.1111\/bjh.15411"],"URL":"https:\/\/doi.org\/10.1111\/bjh.15411","archive":["Portico"],"relation":{},"ISSN":["0007-1048","1365-2141"],"issn-type":[{"value":"0007-1048","type":"print"},{"value":"1365-2141","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,5,22]]},"assertion":[{"value":"2018-02-17","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-04-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2018-05-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}